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CHAPTER 1 
INTRODUCTION 
1.1. INTRODUCTION TO HERBAL MEDICINE  
 For centuries people have used plants for healing. Plant products as parts of 
foods or botanical potions and powders have been used with varying success to cure 
and prevent diseases throughout history. The strong historic bond between plants 
and human health began to unwind in 1897, when Friedrich Bayer and Co. 
introduced synthetic acetyl salicylic acid (aspirin) to the world. Aspirin is a safer 
synthetic analogue of salicylic acid, an active ingredient of willow bark, and was 
discovered independently by residents of both the New and Old worlds as a remedy 
for aches and fevers (IlyaRaskin and David M. Ribnicky, 2002). 
 Herbal medicine is the use of plants, plant parts, their water or solvent 
extracts, essential oils, gums, resins, exudates or other form of advanced products 
made from plant parts used therapeutically to provide proactive support of various 
physiological systems; or, in a more conventional medical sense, to treat, cure, or 
prevent a disease in animals or humans (Weiss RF & Fintelmann V. et al,2000). 
 About 70-80% of the world populations, particularly in the developing 
countries, relyonnon-conventional medicine in their primary healthcare as reported 
by the World Health Organization (Akerele O et al., 1993). 
 In recent years, there has been growing interest in alternative therapies and 
the therapeutic use of natural products, especially those derived from plants (Vulto 
AG & Smet PAGM et al., 1988). This interest in drugs of plant origin is due to 
several reasons, namely, conventional medicine can be inefficient (e.g. side effects 
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and ineffective therapy), abusive and/or incorrect use of synthetic drugs results in 
side effects and other problems, a large percentage of the world, conventional 
pharmacological treatment, and folk medicine and ecological awareness suggest that 
“natural” products are harmless. 
 About 25% of the drugs prescribed worldwide come from plants, 121 such 
active compounds being in current use. Of the 252 drugs considered as basic and 
essential by the World Health Organization (WHO, 1991), 11% are exclusively of 
plant origin and a significant number are synthetic drugs obtained from natural 
precursors. 
 Examples of important drugs obtained from plants are digoxin from Digitalis 
species, quinine and quinidine from Cinchona spp., vincristrine and vinblastine from 
Catharanthus roseus, atropine from Atropa belladonna and morphine and codeine 
from Papaver somniferum (Rates SMK et al.,2001). 
 About 500 plants with medicinal use are mentioned in ancient literature and 
around 800 plants have been used in indigenous systems of medicine. India is a vast 
repository of medicinal plants that are used in traditional medical treatments (Chopra 
et al., 1956).  
 The various indigenous systems such as Siddha, Ayurveda, Unani and 
Allopathy use several plant species to treat different ailments (Rabe and Staden, 
1997).  Herbal medicines as the major remedy in traditional system of medicine 
have been used in medical practices since antiquity. The practices continue today 
because of its biomedical benefits as well as place in cultural beliefs in many parts 
of world and have made a great contribution towards maintaining human health. 
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1.1.1.The role of herbal medicines in traditional healing 
 The World Health Organization (WHO) has recently defined traditional 
medicine (including herbal drugs) as comprising therapeutic practices that have been 
in existence, often for hundreds of years, before the development and spread of 
modern medicine and are still in use today (WHO,1991). Or say, traditional 
medicine is the synthesis of therapeutic experience of generations of practicing 
physicians of indigenous systems of medicine. 
 The traditional preparations comprise medicinal plants, minerals, organic 
matter, etc. Herbal drugs constitute only those traditional medicines which primarily 
use medicinal plant preparations for therapy. The earliest recorded evidence of their 
use in Indian, Chinese Egyptian, Greek, Roman and Syrian texts dates back to about 
5000 years.  
 The classical Indian texts include Rigveda, Atherveda, Charak Samhita and 
Sushruta Samhita. The herbal medicines/traditional medicaments have, therefore, 
been derivedfrom rich traditions of ancient civilizations and scientific heritage. 
1.1.2.Herbal medicine in India 
 India is one of the 12 mega biodiversity centers having over 45,000 plant 
species. Its diversity is unmatched due to the presence of 16 different agroclimatic 
zones, 10 vegetative zones and 15 biotic provinces. The country has 15,000–18,000 
flowering plants, 23,000 fungi, 2500 algae, 1600 lichens, 1800 bryophytes and 30 
million micro-organisms (Drugs and Pharmaceuticals, 1998). 
  India also has equivalent to 3/4 of its land exclusive economic zone in the 
ocean harbouring a large variety of flora and fauna, many of them with therapeutic 
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properties. About 1500 plants with medicinal uses are mentioned in ancient texts and 
around 800 plants have been used in traditional medicine. 
1.1.3.Difference of Herbal and Conventional Drugs 
 Compared with well-defined synthetic drugs, herbal medicines exhibit some 
marked differences, namely: 
• The active principles are frequently unknown 
• Standardization, stability and quality control are feasible but not easy; 
• The availability and quality of raw materials are frequently problematic; 
• Well-controlled double-blind clinical and toxicological studies to prove their  
efficacy and safety are rare; 
• Empirical use in folk medicine is a very important characteristic; 
• They have a wide range of therapeutic use and are suitable for chronic 
treatments; 
• The Occurrence of undesirable side effects seems to be less frequent with herbal 
• Medicines, but well-controlled randomized clinical trials have revealed that they 
also exist; 
• They usually cost less than synthetic drugs (Calixto J B et al., 2000). 
1.1.4. Relationship between Ayurveda and modern medicine 
 Ayurveda, one of the major traditional forms of medical practice in India, 
has produced many useful leads in developing medications for chronic diseases. 
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Almost 25 centuries ago, Hippocrates proclaimed, Let food be the medicine and 
medicine be the food. (David J. Newman & Gordon M. Cragg, 2003). 
 Combining the strengths of the knowledge base of traditional systems such 
as Ayurveda with the dramatic power of combinatorial sciences and High 
Throughput Screening will help in the generation of structure- activity libraries. 
Ayurvedic knowledge and experiential database can provide new functional leads to 
reduce time, money and toxicity –the three main hurdles in drug development. These 
records are particularly valuable, since effectively these medicines have been tested 
for thousands of years on people. Efforts are underway to establish pharmaco 
epidemiological evidence base regarding safety and practice of ayurvedic medicines.  
1.1.5. Herbal medicine standardization 
 In indigenous/traditional systems of medicine, the drugs are primarily 
dispensed as water decoction or ethanolic extract. Fresh plant parts, juice or crude 
powder are a rarity rather than a rule. Thus medicinal plant parts should be authentic 
and free from harmful materials like pesticides, heavy metals, microbial or 
radioactive contamination, etc. The medicinal plant is subjected to a single solvent 
extraction once or repeatedly, or water decoction or as described in ancient texts.  
 The extract should then be checked for indicated biological activity in an 
experimental animal model(s).The bioactive extract should be standardized on the 
basis of active principle or major compound(s) along with fingerprints. 
 The next important step is stabilization of the bioactive extract with a 
minimum shelf-life of over a year. The stabilized bioactive extract should undergo 
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regulatory or limited safety studies in animals. Determination of the probable mode 
of action will explain the therapeutic profile.  
 The safe and stable herbal extract may be marketed if its therapeutic use is 
well documented in indigenous systems of medicine, as also viewed by WHO. A 
limited clinical trial to establish its therapeutic potential would promote clinical use. 
The herbal medicines developed in this mode should be dispensed as prescription 
drugs or even OTC products depending upon disease consideration and under no 
circumstances as health foods or nutraceuticals. (V.P.Kamboj et al., 2000). 
1.1.6. Pharmacological Actions of Herbal Medicine 
1.1.6.1. Anti-inflammatory activity 
 The extract of Achillea millefolium, Artemisia vulgaris, Bauhinia 
tarapotensis, Curcuma longa, Forsythia suspense, Houttuynia cordata, Glycyrrhiza 
uralensis, Lonicera japonica, Ruta graveolens, Securidaca longipedunculata and 
Valeriana wallichii have shown anti-inflammatory activity. 
1.1.6.2. Antidiabetic activity 
 From earliest period, people have using herbal plants as home remedies for 
the treatment of diabetics. A variety of  herbal plants with antidiabetic activity are 
Abroma augusta, Acacia melanoxylon, Acacia modesta, Acacia nilotica, Aconitum 
ferox, Adathoda vasika, Adiantum capillus, Adiantum incisum, Agrimonia eupatoria, 
Allium sativum, Aloe barbadensis, Althea officinalis, Apium grraveolens, 
Commiphora abyssinca, Embilica officinalis, Eucalyptus globules, Ginseng panax, 
Gymnema sylvestre, Inula helenium, Juniperus commmunis, Medicago sativa, 
Nigella sativa, Orthosiphon stamineus, Panex quinquefolius, Polygala senega, 
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Plantago ovata, Punica granatum, Salvia officinalis, Tanacetum vulgare, Tecoma 
stans, Turnera diffusa. 
1.1.6.3. Analgesic activity 
 The extracts of Bougainvilla spectabilis, Chelidonium majus, Ficus 
glomerata, Dalbergia lanceolaria, Glaucium grandiflorum, Glaucium paucilobum, 
Nepta italic, polyalthia longifola, Sida acuta, Toona ciliate, Zataria multiflora and 
Zingiber zerumbet are used as analgesic agents. 
1.1.6.4. Anticancer activity 
   Medicinal plant products exhibiting anticancer activity continue to be the 
subject of extensive research aimed at the development of drugs for treatment of 
different human tumors. The medicinal  plants used for the the treatment of cancer 
are, Celastrus paniculantus, Embelica ribes, Ficus glomerata, Ficus racemose, 
Ocimum basilicum, Plumbagozeylanica, Terminalia chebula, Tylophora indic, Wrighti 
tinctoria. The extract used for treatment of breast cancer are Buthus martensi, Colla 
cornu, Herb epimedii, Fructus lycii, Radix angelicae, Rhizoma corydalis, Rhizoma 
curculigins, Radix paeoniae, Squama manitis, Tuber curcumae. 
1.1.6.5. Anti-ageing activity 
  Cell membranes are particularly susceptible for to the hostility of free 
radicals. When nucleus is injured, the cell loses its ability to replicate itself. The 
impaired cell replication results in destabilized immune system, skin aging and 
many age related disorders. Various antioxidants neutralize the free radicals and 
prevent oxidation on a cellular level. The most effectual antioxidants include pine 
bark extract, grape seed extract and blue berries were effectual against hostility of 
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free radicals. Some commonly used herbs as anti-ageing agents are Allium sativum, 
Arnica montana, Cucumis satiivum, Curcuma longa, Ficus bengalenis, Lycium 
barbarum, Ocimum sanctum, Panax ginseng, Prunus amygdalis, Santalum album, 
Rosa damascene and Withania somnifera. 
1.1.6.6. Antifertility activity 
 Plant drugs have involved in the concentration of many scientists as a 
primary source of naturally occurring fertility regulating agents because of their little 
or no side effects. The plant that have been reported to have anti-fertility activity are 
Amaranthus retroflexus, Artrabotrys odoratissimus, Barberis vulgaris, Carica 
papaya, Evodia rutacapra, Fatsia horrid, Hibiscus rosasinensis, Lornicera ciliosa, 
Pisum sativum, Raphanus sativus, Taxus baccata and Verbena officinalis. 
1.1.6.7. Anti-psoriasis activity 
 A variety of natural proprietary formulas and preparations containing plant 
materials have been used to provide symptomatic relief in psoriasis. The different 
herbal remedies for psoriasis are turmeric, curcumin, shark cartilage extract, oregano 
oil, milk thistle. Various antimicrobial agents like Azardiracta indica, Calendula 
officinalis, Cassia tora, Wrightia tinctoria have been used in the treatment of 
psoriasis. 
1.1.6.8. Antidepressant activity 
 A number of nutritional and herbal supplements have shown promise for 
alternative treatment for depression. A large number of plants have potential 
function to treat depression which are described as Bacopa monniera, Pana 
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quinquefolius, Piper methysticum, Rhodiola rosea, Valeriana officinalis and 
Hypericum perforatum. 
1.1.6.9. Anti-vitiligo activity 
 Anti-vitiligo oil is a herbal remedy manufactured with potent herbs and is 
produced with traditional methods and is also a complete traditional formulation. 
The plants which can be used in the treatment of vitiligo are Acorus calamus, 
Adiantum capillus, Boswellia serrata, Cassia angustifolia, Cassi tora, Cinnamon 
cassia, Fumaria officinalis, Glycerrhiza glabra, Psoralea cordyfolia, Vitis vinifera, 
Zingiber officinale and Zizyphus sativa. 
1.1.7. Phyto-constituents and It’s Actions 
1.1.7.1. Alkaloids:     
 Alkaloids have derived from plant sources, they are basic, they contain one 
or more nitrogen atoms (usually in heterocyclic ring) and they usually have marked 
physiological actions on man or other animals. 
  Alkaloids are mainly used as antitumor (vincristine and vinblastine), 
anticholinergic (atropine), stimulant (caffeine), antimalarial and antipyretic 
(quinine), cough medicine and analgesic (codeine) etc… 
1.1.7.2. Flavonoids: 
 Flavonoids are the largest class of polyphenols. Chemically they may be 
defined as a group of polyphenolic compounds consisting of substances that have 
two substituted benzene rings connected by the chain of three carbon atoms and an 
oxygen bridge. 
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 Flavonoids possess antibacterial, anticancer, anti-inflammatory actions and 
used in the treatment of cardiovascular diseases. 
1.1.7.3. Glycosides: 
  Glycosides may be defined in general as the organic compounds from plants 
or animal sources which on enzymatic or acid hydrolysis give one or more sugar 
(glycon) moieties along with non-sugar (aglycon) moiety. 
  Glycosides are used as cardio tonic, purgative, anti -rheumatic, analgesic, 
demulcent etc… 
1.1.7.4. Tannins: 
 Tannins are chemically defined as the mixture of complex organic 
substances where in polyphenols are present with O-dihydroxy or O-trihydroxy 
groups on a phenyl ring. 
 Tannins are used as mild antiseptic, in the treatment of diarrhea and to 
forestall minor hemorrhages. 
1.1.7.5. Carbohydrates: 
 Carbohydrate may be defined as polyhydroxy aldehydes or polyhydroxy 
ketonesor compounds which produce them on hydrolysis, Carbohydrates are mainly 
used as demulscent, laxative, antidiarrhoeal, pharmaceutical agents etc… 
1.1.7.6. Fixed oils and fats: 
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  These are reserved food materials of plants and animals. Those which are 
liquid at 15.5oC to 16.5oC are called as fixed oils; while those which are solid or 
semisolid at above temperature are called as fats. 
1.1.7.7. Muscilage: 
 These are polysaccharide complexes of sugar and amino acids, usually 
formed from the cell wall. They are insoluble in alcohol but swell or dissolve in 
water. 
 They are used as emulsifiers, suspending agent, demulsent etc… 
1.1.7.8. Proteins and amino acids: 
  Proteins are complex nitrogenous organic substances of plant andanimal 
origin. They are of great importance in the functioning of living cells. They contain 
carbon, hydrogen, nitrogen, oxygen and rarely Sulphur. The ultimate product of 
complete hydrolysis of proteins, either by chemical reagents or enzymes are amino 
acids. 
 Aminoacids are group of organic compounds containing two functional 
groups- amino and carboxyl. The amino group is basic while the carboxyl group is 
acidic in nature. 
 Proteins are mainly used as digestant, anti-inflammatory agent, anti-
coagulant, nutritive and dietary suppliments. (Kokate et al., 2012). 
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1.2. INTRODUCTION TO CENTRAL NERVOUS SYSTEM: NEURO-
TRANSMISSION AND DISORDERS 
Central nervous system (CNS) is functionally very complex than any other 
systems in the body as the relationship between the behavior of individual cell and 
that of the whole organ is less direct. CNS includes brain and spinal cord. Brain is 
an array of interrelated neural systems that regulate their own and each other’s 
activity through intercellular chemical transmission.  
1.2.1. Neurochemical Transmission in CNS: 
Four processes occur in relation to nerve transmission in CNS 
neurotransmission, neuromodulation, neuromediation and mediation through 
neurotropic factors. Analogously such chemical secretions are called 
neurotransmitters, neuromodulators, neuromediators and neurotropic factors 
respective. 
1.2.1.1. Neurotransmitters: 
Synthesized in presynaptic neurons and are released into synaptic cleft to 
rapidly stimulate or inhibit postsynaptic neurons. 
Eg: Acetylcholine, dopamine, norepinephrine (epinephrine in reticular 
formation), 5-hydroxytryptamine, gamma-amino butyric acid, glycine, glutamate, 
aspartate, endogenous opioids, cholecystokinin, tachykinins etc… 
1.2.1.2. Neuromodulators: 
They are released by neurons and astrocytes to produce slower pre-or 
postsynaptic responses. Neuromodulation generally relates to synaptic plasticity that 
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means long-term changes in synaptic transmission, connectivity and efficacy 
following pathological damage (as in epilepsy or drug dependence) or following 
physiological alterations in neuronal activity (as in learning and memory). 
eg. Carbon dioxide, locally released adenosine, some purines, peptides, 
prostaglandins, arachidonic acid metabolites and Nitric oxide.  
1.2.1.3. Neuromediators: 
They are second messengers that play crucial role in elicitation of 
postsynaptic responses produced by neurotransmitters. eg. cAMP, cGMP and 
inositol phosphate.  
1.2.1.4. Neurotropic factors: 
They are mainly released by CNS neurons, astrocytes and microglia and act 
longer than neuromodulators to regulate the growth and morphology of neurons and 
control long-term changes in brain (synaptic plasticity, remodeling, phenotype 
characteristics) mainly by affecting gene transcription by acting through tyrosine 
kinase-linked receptors.  eg. Cytokines, chemokines, growth factors.  
1.2.2. CNS Neurotransmitters and their receptors 
1.2.2.1. Amino Acids: 
The CNS contains high concentrations of certain amino acids mainly, 
glutamate and gamma-amino butyric acid (GABA). The dicarboxylic acids 
(glutamate and aspartate) produce excitation and monocarboxylic ω-amino acids 
(GABA, glycine, β-alanine and taurine) produce inhibition. 
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GABA and its receptors:  
GABA is the major inhibitory neurotransmitter in the CNS. It has three 
receptor subtypes – GABAA (postsynaptic ionotropic receptor and is a ligand-gated 
Cl- ion channel, agonists- muscimol, isoguvacaine and antagonists- bicuculline, 
picrotoxin), GABAB (presynaptic metabotropic Gi-protein coupled receptor and 
inhibits adenylyl cyclase, activates K+ channels and reduce Ca2+ conductance, 
agonist- baclofen), GABAC (transmitter gated Cl
- channel). PentamericGABAA 
receptor is most abundant in the brain and has seven subunit families six α, three β, 
three γ and single δ, ε, π, and θ in uncertain stoichiometry. The inclusion of variant 
ratios of subunits in GABAA alters the pharmacological profile of various 
benzodiazepines.   
GABAA receptor has various binding sites that include a GABA binding site, 
a modulatory site to bind benzodiazepines (at the interface between α and γ subunits, 
also their antagonist such as flumazenil and inverse agonist such as carbolins), the 
modulatory as well as blocking site at Cl- ion channel as for barbiturates (α and β 
subunits) and picrotoxin.   
 
Figure 1.1 GABAA Receptor  
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Benzodiazepines (BZDs) enhances GABA activity by increasing the 
frequency of channel opening and barbiturates potentiates GABA mediated 
inhibition by prolonging the duration of channel opening and at higher doses 
exhibits GABA mimetic action.  
The most commonly found isoform of GABAA is 2α1:1β2:1γ2. Studies on 
transgenic mice led to the findings that α1 subunits in GABAA mediate sedation, 
amnesia and possibly antiepileptic actions of BZDs. Α2 subunits mediate antianxiety 
and muscle relaxant actions and α5 subunit is involved in at least some of the 
memory impairment caused by BZDs.  
Glycine and its receptors:  
 Glycine is another inhibitory neurotransmitter present mainly in medulla, 
spinal cord, lower brain stem and the retina. Its agonists are βalanine, taurine and 
antagonist is strychnine. Glycine receptor is also linked to Cl- ion channel. Glycine 
and its competitive antagonist strychnine bind to α subunit while tetanus toxin acts 
by preventing the release of Glycine and causing excessive hyper-excitability and 
violent muscle spasms (lock jaw).  
Glutamate, Aspartate and their receptors:  
Glutamate and aspartate are the two excitatory neurotransmitters 
concentrated in cortex, basal ganglia and sensory pathways. Besides acting as 
neurotransmitters they also play a role in intermediary metabolism in neural tissue, 
viz., in detoxification of ammonia in brain, as building blocks in the synthesis of 
peptides, proteins and GABA.  
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 There are five receptors for excitatory neurotransmitters, they are; 
➢ NMDA (N-methyl-D-aspartate) receptor: 
 Ionotropic receptors linked to Ca2+ and involved in neurophysiological and 
pathological processes like memory acquisition, development of synaptic plasticity, 
epilepsy and neuronal excitotoxicity due to cerebral ischemia. NMDA receptor is a 
pentamer composed of subunits NR-1 and NR-2. It has various binding sites for 
binding glutamate (or NMDA), modulatory site that binds glycine (glutamate is 
ineffective unless glycine is bound to this site), polyamines (spermine and spermi-
dine) binding site which facilitates channel opening, binding site for phencyclidine 
(PCP binding site) and related antagonists (ketamine), a voltage dependant Mg2+ 
binding site (at resting state Mg2+ blocks the receptor) and a voltage-independent 
Zn2+ binding site near the mouth of the channel (Zn2+ produces voltage independent 
inhibitory action on NMDA receptor ion channel).  
 
Figure 1.2. NMDA Receptor  
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➢ AMPA (α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid) receptor: 
 They are pentameric ionotropic receptor linked to Na+ and consists of 
GLUR1-4 subunits. AMPA and quisqualate are the agonists.  
➢ Kainate receptor: 
They are pentameric ionotropic receptor linked to Na+ and consists of 
GLUR5-7 and KA1-2 subunits. Kainate and domoate are agonists.  
➢ AP-4 (1,2-diamino-4-phosphobutyrate): 
They are inhibitory autoreceptor.  
➢ ACPD (1-aminocyclopentane-1,3-dicarboxylic acid): 
G-protein coupled receptors and either stimulate phospholipase-C-IP3 system 
or inhibit and adenylyl cyclase.  
Acetylcholine (ACh) and its receptors:  
Cholinergic neurons are present in cerebral cortex, ascending reticular activating 
system, basal ganglia, limbic system, cerebellum and spinal cord. Ach modulates 
arousal, respiration, motor activity, vertigo and memory. Both muscarinic and NN 
receptors are present in brain. Centrally acting antimuscarinic drugs are useful in 
Parkinsonism and anticholinesterases such as tacrine, donepezil and rivastigmine are 
used to improve cognitive functions in Alzheimer’s disease.  
1.2.2.2.Biogenic amines:  
 Amine neurotransmitters include dopamine, norepinephrine (epinephrine), 5-
hydroxytryptamine and histamine.  
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Dopamine and its receptors: 
Dopamine is primarily an inhibitory neurotransmitter. Its deficiency causes 
extrapyramidal disturbances. There are five receptors identified – D1-5. Activation of 
D1 and D5 stimulate adenylyl cyclase and increase the release of cAMP; D2-4 inhibits 
adenylyl cyclase and decrease the release of cAMP. The locations of these receptors 
are – D1 – Nigrostriatal pathway (putamen, nucleus accumbens and olfactory 
tubercle). Its inhibition causes extrapyramidal disorders.  
D5 – Hypothalamus and hippocampus. Its exact role is not known.  
D2 – Striatum, substantia nigra and pituitary. It is involved in the control of the 
behavior, voluntary movements, prolactin release and other endocrine consequences.  
D3 – Midbrain, nucleus accumbens and hypothalamus.  
D4 – Mesocortical pathway (frontal cortex, medulla and midbrain). Some of the 
atypical neuroleptics possess D3 and D4 antagonistic activity. 
Norepinephrine and Epinephrine:  
 Norepinephrine is a neurotransmitter of brainstem neurons within locus 
cerulus (pons and neurons of reticular formation) with projections to cortex, 
cerebellum and spinal cord. In CNS it is thought to modulate affective disorders 
(depression), learning, memory, arousal and pain perception. Mammalian CNS 
contains both α- and β-adrenoceptors. Unlike dopamine and norepinephrine, 
concentration of epinephrine is very low and is localized primarily in reticular 
formation and its precise role in CNS is not known.  
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5-hydroxytryptamine (5-HT) and its receptors:  
 Serotonergic neurons are found primarily near the midline raphe nuclei of the 
brainstem and project to the cortex, cerebellum and the spinal cord. 90% of 5-HT is 
present in enterochromaffin cells and remaining 10% in brain and platelets, yet it is 
implicated as a potential neurotransmitter in the mediation of wide variety of brain 
functions. It plays important role in schizophrenia, depression, temperature 
regulation and eating disorders. It is a precursor of melatonin in pineal gland. It may 
also be involved in the hypothalamic control of the release of pituitary hormones. Its 
receptors are 5-HT1-7 with several subtypes. All the receptors are metabotropic, 
except 5-HT3 which is ionotropic.5-HT1A receptor agonists (buspirone) are used to 
treat anxiety disorders, 5-HT1D receptor agonists (sumatriptan) are used to treat 
migraine and cluster headaches, 5-HT2A/2C receptor antagonists (clozapine)  are used 
to treat schizophrenia, 5-HT3 antagonists (ondansetron) are used to prevent 
chemotherapy induced emesis, 5-HT4 agonists (metoclopramide) are used as 
antiemetic and prokinetic drugs and 5-HT reuptake inhibitors (SSRIs- fluoxetine) 
are used to treat depression and obsessive-compulsive disorders.  
Histamine and its receptor:  
Histaminergic neurons originate form posterior hypothalamus, and project to 
cerebral cortex, limbic system, caudate, putamen, globus pallidus, brain stem, 
substantia nigra, dorsal raphe, cerebellum and spinal cord. Histaminergic neurons 
and postsynaptic central H1 receptors play a major role in arousal, in coupling 
neuronal activity with cerebral metabolism and in neuroendocrine regulation.  
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Peptides: 
There are number of peptide neurotransmitters in CNS involved in diverse 
functions of CNS besides their peripheral actions. Some of them are vasopressin 
(facilitate learning and memory), oxytocin (mating and parenting behavior), 
tachykinins (pain transmission), neurotensin (lowers body temperature), vasoactive 
intestinal peptide (pain transmission), endogenous opioids (analgesia, euphoria and 
reduces stress), cholecystokinin (appetite regulation), angiotensin II (centrally 
influences drinking behavior) and neuropeptide Y (increases feeding/orexigenic, 
hypothermia, cerebral vasoconstriction). 
Imbalance among these various neurotransmitters &/or damage to the 
neurons or parts of CNS leads to various disorders.  
1.2.3. CNS Disorders  
1.2.3.1. Motor Disorders: 
Epilepsy: 
Damage to the cerebral cortex and imbalance between excitatory and inhibitory 
neurotransmitters of brain results in epilepsy. The behavioral manifestations of a seizure 
are determined by the functions, normally served by the cortical site at which seizure 
arises.  
1.2.3.2. Behavioral Disorders: 
Behavioral disorders result due to damage to one or more parts of CNS, i.e., 
cortex, limbic system, hypothalamus and brainstem.  
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Depression: 
Deficiency of aminergic transmission in CNS results in depression.  
Mania: 
Excess of aminergic transmission in CNS results in mania. It is particularly 
associated with changes in mood. 
Schizophrenia: 
Functional over activity of dopamine in limbic system or cerebral cortex 
leads to schizophrenia. It is particularly associated with changes in thought 
processes.  
1.2.3.3. Neurodegenerative Disorders: 
Alzheimer’s disease: 
Loss of hippocampal and cortical neurons which leads to abnormalities of 
memory and cognitive ability.  
Parkinson’s disease and Huntington’s disease: 
Loss of neurons of basal ganglia leads to abnormalities in control of 
movement.  
Amyotrophic lateral sclerosis (ALS): 
Degeneration of spinal bulbar and cortical motor neurons lead to muscular 
weakness. 
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There are several other CNS diseases that result due to cerebrovascular 
accidents, physical injury to CNS, infections, etc.  
1.3. INTRODUCTION TO EPILEPSY 
Epilepsy is a common and frequently devastating disorder affecting millions 
of people worldwide. The term seizure refers to a transient alteration of behavior due 
to the disordered, synchronous and rhythmic firing of populations of brain neurons. 
The term epilepsy refers to a disorder of brain function characterized by the periodic 
and unpredictable occurrence of seizures. The word fit is often used colloquially to 
describe an epileptic seizure. Convulsionsare involuntary, violent and spasmodic or 
prolonged contractions of skeletal muscle. That means, a patient may have epilepsy 
without convulsions and vice versa. 
1.3.1. Signs and Symptoms of Seizures 
 Seizures have a beginning, middle and end. Sensory, emotional and physical 
symptoms appear before, during and after seizures.   
➢ Sensory / Thought Symptoms:   
Aura / early seizure symptoms (warnings)- visual loss or blurring, racing 
thoughts, stomach feelings, strange feelings and tingling feeling.  
Seizure symptoms - Black out, confusion, deafness/sounds, electric shock 
feeling, loss of consciousness, smell, spacing out, out of body experience and visual 
loss or blurring. 
Post-ictal/after-seizure symptoms - Memory loss and writing difficulty.  
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➢ Emotional Symptoms: 
Aura / early seizure symptoms (warnings) - Fear/panic, pleasant feeling.  
Seizure symptoms – Fear/panic.  
Post-ictal/after-seizure symptoms- Confusion, depression and sadness, fear, 
frustration, shame/embarrassment.  
➢ Physical Symptoms:  
Aura/early seizure symptoms (warnings) - Dizziness, headache, light 
headedness, nausea and numbness.  
Seizure symptoms - Chewing movements, convulsions, difficulty in talking, 
drooling, eyelid fluttering, eyes rolling up, falling down, foot stomping, hand 
waving, inability to move, incontinence, lip smacking, making sounds, shaking, 
staring, stiffening, swallowing, sweating, teeth clenching/grinding, tongue biting, 
tremors, twitching movements, breathing difficulty and heart racing.  
Post-ictal/after-seizure symptoms - Bruising, difficulty talking, injuries, 
sleeping, exhaustion, headache, nausea, pain, thirst, weakness, urge to 
urinate/defecate.  
1.3.2. Age and Onset of Epilepsy  
Epilepsy primarily affects the very young and the very old, although anyone 
can get epilepsy at anytime. Twenty percent of cases develop before the age of five. 
Fifty percent develop before the age of 25.  
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1.3.3. Cause of Epilepsy 
In about 70 percent of cases there is no known cause. Of the remaining 30 
percent, the following are the most frequent causes:  
• Arteriovenous malformation (AVM)   
• Head injury   
• Intoxication with drugs   
• Drug toxicity, eg. aminophylline or local anesthetics   
• Brain tumors  
• Normal doses of certain drugs that lower the seizure threshold, eg. Tricyclic 
antidepressants   
• Infections, eg. encephalitis or meningitis   
• Febrile convulsions    
• Metabolic disturbances, eg. hypoglycemia, hyponatremia or hypoxia   
• Sudden withdrawal of certain drugs eg. Anticonvulsants and sedatives such as 
barbiturates, and benzodiazepines; alcohol.   
• Space-occupying lesions in the brain (abscesses, tumors)   
• Eclampsia.   
• Binaural beat brainwave entrainment may trigger seizures in both epileptics and 
non-epileptics   
• Stroke may cause seizures, eg. embolic strokes, cerebral venous sinus 
thrombosis.  
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Figure 1.3. Causes of Seizures 
1.3.4. Classification of Seizures 
1.3.4.1. Partial Seizures (Localized/Focal Seizures): 
➢ Simple Partial Seizures (Jacksonian Epilepsy) (SPS): 
Duration 20-60sec, consciousness is not impaired. SPS results from rapid 
neuronal discharges in one part of the brain, usually the cortex or limbic system. 
These seizures take different forms like motor, sensory, autonomic and psychic and 
are characterized by strange or unusual sensations, for example odors or visual 
abnormalities, sudden or restless movement, hearing distortion, stomach discomfort, 
and a sudden sense of fear. The International League Against Epilepsy (ILAE) 
introduced International Classification for Epilepsies and Epileptic Syndromes 
(ICES) which categorized simple partial seizures into four subtypes. 
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• Motor: (cause changes in muscle activity. For example, a person may have 
abnormal movements such as jerking of a finger or stiffening of part of the 
body). 
• Sensory: (cause changes in any one of the senses. People with sensory seizures 
may smell or taste things that aren't there; hear clicking, ringing, or a person's 
voice when there is no actual sound; or feel a sensation of "pins and needles" or 
numbness). 
• Psychic: (cause changes in how patients think, feel, or experience things. They 
may have problems with memory, garbled speech, and inability to find the right 
word, or trouble understanding spoken or written language. They may suddenly 
feel emotions like fear, depression, or happiness with no outside reason. Some 
may feel as though they are outside their body.  
• Autonomic: (cause changes in the part of the nervous system that automatically 
controls bodily functions. These include strange or unpleasant sensations in the 
stomach, chest, or head; changes in the heart rate or breathing; sweating; or 
goose bumps).  Simple partial seizures lead to complex partial seizures or to 
tonic-clonic convulsions.   
 
 
Figure 1.4. Simple Partial Seizures 
Chapter 1 Introduction 
Dept of Pharmacology 27 JKKMMRF College of Pharmacy 
➢ Complex Partial (CPS/Psychomotor/Temporal Lobe Epilepsy) Seizures: 
Duration 30sec-2min with impaired consciousness. CPS occurs when 
epileptic activity spreads to involve a major portion of the brain but does not become 
generalized. They often are preceded by aura and occur after a simple partial seizure 
particularly when it is of temporal lobe origin. CPS often begin with a blank look or 
stare and then may progress to chewing or uncoordinated activity, meaningless bits 
of behavior, which appear random and clumsy (automatisms) and patients may 
appear afraid, try to run and struggle. These seizures are followed by a state of 
confusion that lasts even longer. Once the pattern of the seizures is established it will 
usually be repeated with each subsequent seizure. CPS sometimes resists 
anticonvulsant medication. In some cases CPS may lead to tonic-clonic seizures.   
 
Figure 1.5. Complex Partial Seizures 
➢ Partial Seizures evolving to Secondarily Generalized Seizures: 
 Duration 1-2min. Seizures of this kind start as a partial seizure that is, they 
start in one limited area of the brain and then (sometimes so quickly that the partial 
seizure is hardly noticed) the seizure spreads throughout the brain, becoming 
"generalized." 
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1.3.4.2. Generalized Seizures: 
➢ Absence (Petit mal) Seizures: 
Epileptic activity occurs throughout the entire brain. It is a milder type of 
activity, however, causes unconsciousness without causing convulsions. An absence 
seizure consists of a period of unconsciousness with a blank stare, and begins and 
ends abruptly, without warning. There is no confusion after the seizure; seizures 
may be accompanied by chewing movements, rapid breathing, or rhythmic blinking. 
Absence seizures are short, usually lasting 2-10 seconds. They are very mild, and 
may go unnoticed and may recur frequently during the day. 
Typical Absence Seizures: 
 They are non-convulsive and muscle tone is usually preserved. The seizure 
event usually lasts for less than 10 seconds in duration. 
Atypical Absence Seizures: 
They are longer in duration than typical absence seizures with or without loss 
in muscle tone and often tonic/clonic-like movements are observed.   
 
Figure 1.6. Absence Seizures 
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➢ Myoclonic Seizures: 
 Occur in several different types of epilepsy. The seizures involve abrupt 
muscle jerks in part or all of the body, eg. a hand suddenly flinging out, shoulder 
shrug, foot kicking, or the whole body may jerk. The events may occur individually, 
or in a series. Consciousness is not impaired. Myoclonic Seizures are not tics or 
“startle” responses.  
➢ Clonic seizures: 
They are characterized by repetitive muscle jerks. 
➢ Tonic Seizures: 
Characterized by rigid violent muscular contraction with stiff and fixed 
extended limbs.  
➢ Tonic-Clonic (Grand mal) Seizures: 
 
Figure 1.7.  Generalized Tonic-Clonic Seizures 
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Generalized seizures occur when epileptic activity occurs throughout the 
brain. Patient becomes unconscious from the start, and will have a major convulsion 
with both tonic (stiffening) and clonic (jerking) phase. After the seizure, the patients 
are unconscious and then groggy for a while. They may want to sleep. There will be 
no memory of what went on during the seizure. The seizure begins with a fall, 
possibly accompanied by a sudden cry, followed by tonus and then, after a while, 
clonus. There may be shallow breathing or temporarily suspended breathing, with 
bluish skin or lips and loss of bladder or bowel control. Towards the end of the 
seizure, patient may salivate profusely. Tonic-clonic seizures usually last 1 to 3 
minutes, seldom longer.  
➢ Atonic Seizures:  
Although relatively uncommon, they are hard to deal with as they occur 
without warning. The individual abruptly loses consciousness, collapses and falls to 
the floor. There is no convulsion, but the patients may injure themselves as they fall. 
Recovery occurs after a few seconds.   
1.3.4.3. Unclassified Epileptic Seizures (Status Epilepticus): 
Status epilepticus (SE) refers to continuous seizure activity with no recovery 
between successive seizures. It is a life-threatening condition. A tonic-clonic seizure 
lasting longer than 5 minutes (or two minutes longer than a given person's usual 
seizures) is usually considered grounds for calling the emergency services.  
Chapter 1 Introduction 
Dept of Pharmacology 31 JKKMMRF College of Pharmacy 
 
Figure 1.8. Status Epilepticus 
1.3.5. Seizure Syndromes: 
There are many different epilepsy syndromes, each presenting with its own 
unique combination of seizure type, typical age of onset, EEG findings, treatment, 
and prognosis. Below are some common seizure syndromes:  
• Infantile Spasms (West syndrome) 
• Childhood Absence Epilepsy 
• Dravet's Syndrome 
• Benign Focal Epilepsies of Childhood 
• Juvenile Myoclonic Epilepsy (JME)   
• Temporal Lobe Epilepsy 
• Fetal Alcohol Syndrome 
• Frontal Lobe Epilepsy 
• Lennox-Gastaut Syndrome 
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1.3.6. Endogenous Anti-seizure Substances 
 It is suggested that some sort of regulatory mechanism must be existing in 
the body as spontaneous arrest of seizure activity occurs after an attack and also 
brain remains seizure free for sometime between the two intervening attacks 
(postictal refractory period). Elevated adenosine levels have been reported 
immediately after the seizure activity both in animal models as well as in patients. 
Adenosine has been shown to inhibit spontaneous firing of cells in virtually all areas 
of brain including cerebral cortex. It causes hyperpolarization and exhibits A1 
receptor mediated anticonvulsant effects in animal models when administered 
exogenously. Since it is released postictal and it is not tonically active, A1 receptor 
antagonists per se do not exhibit any convulsant activity (www.shodhganga. 
inflibnet.ac.in)  
1.4. INTRODUCTION TO ANXIETY 
Anxiety is a subjective feeling of unease, discomfort, apprehension or fearful 
concern accompanied by a host of autonomic and somatic manifestations. Anxiety is 
a normal, emotional, reasonable and expected response to real or potential danger. 
However, if the symptoms of anxiety are prolonged, irrational, disproportionate 
and/or severe; occur in the absence of stressful events or stimuli; or interfere with 
everyday activities, then, these are called Anxiety Disorders (DSM IV-TR, 2000). 
Anxiety disorders are among the most common mental, emotional, and behavioral 
problems (Kessler et al., 2005a, 2005b; Olatunji et al., 2007; Kessler & Wang, 
2008). These affect one-eighth of the total population worldwide, and have become 
a very important area of research interest in psychopharmacology (Eisenberg et al., 
1998; Dopheide & Park, 2002; WHO, 2004). 
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In addition to the high prevalence, anxiety disorders account for major 
expenditure for their management (DuPont et al., 1996); and anxiety disorders have 
a substantial negative impact on quality of life (Gladis et al., 1999; Mendlowicz & 
Stein, 2000; Olatunji et al., 2007). 
1.4.1. Symptoms of Anxiety Disorders: 
The subjective experience of anxiety typically has two components namely 
physical component and emotional component which affect the cognitive processes 
of the individual (Cates et al.,1996; Charles and Shelton, 2004; Augustin, 2005; 
Shri, 2006; Rang et al.,2007) and these have been shown in F 
 
Emotional sensations  Physical sensations 
Headache, nausea, vomiting,  
sweating, trembling, stomach  
pain, ulcers,  diarrhea, 
tingling, weakness, body 
ache, feeling  
shortness of breath, hot 
flashes or chills, increased 
blood pressure and heart 
rate, etc. 
Nervousness, worry, fear, 
irritability, insecurity, 
isolation  
from others, self-
consciousness,  
desire to escape, feeling that 
one is going to die, etc. 
 
These impairs cognitive processes 
(Thinking, decision-making ability, 
perceptions of the environment, 
learning, memory and concentration). 
 
 
Figure 1.9. Symptoms of anxiety 
 
Symptoms of Anxiety disorders 
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Table. 1.1. Etiology of Anxiety Disorder 
Biological  causes Psychological  causes Social  causes 
Heredity 
Neurotransmitter  
imbalance 
Illness 
Medications 
Nutritional factors 
Personality traits 
Low self-esteem 
Cognitive dissonance 
Negative emotions 
Inter and/or intra-
personal conflicts 
 
Adverse Life Experiences 
Lack of social support 
Work stress 
Lack of social skills 
Changing values 
Conflict of societal norms 
Terrorism 
 
1.4.2. Etiology: 
Anxiety disorders are among the most frequent mental disorders encountered in 
clinical practice (Kirkwood & Melton, 2002). These represent a heterogenous group 
of disorders, probably with no single unifying etiology. Various psychodynamic, 
psychoanalytic, behavioral, cognitive, genetic and biological theories have been 
proposed to explain the etiology and pathophysiology of anxiety disorders (Cates et 
al., 1996). These are said to be Bio-Psycho-Social factors that contribute to anxiety 
disorders (Pies, 1994; White, 2005; Wong, 2006). 
Neurotransmitter balance in normal individuals Excitatory 
neurotransmitters Inhibitory neurotransmitter 
Neurotransmitter imbalance in individuals with anxiety disorders 
Danger or a perceived threat  
Activation of the Hypothalamic-Pituitary-Adrenal   GABA, 
Serotonin 
 
Corticotropin-Releasing Factor 
Cholecystokinin B  
Neuronal firing            Norepinephrine 
Excitatory neurotransmitters Inhibitory neurotransmitters 
 
Figure 1.10. Neurotransmitters involved in occurrence of anxiety disorders. 
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1.4.2.1. Biological factors 
➢ Genetic factors: 
Genetic factors predispose certain people to anxiety disorders. There is a higher 
chance of an anxiety disorder in the parents, children and siblings of a person with 
an anxiety disorder than in the relatives of someone without an anxiety disorder 
(Torgersen, 1983; Weissman, 1993; Goldman, 2001). 
➢ Neurotransmitter imbalance: 
Brain imaging and functional studies have shown that several neurotransmitters 
are linked to the neurobiology of anxiety (Cates et al., 1996 Sandford et al., 2000; 
Millan, 2003; Augustin, 2005).  
1.4.2.2. Psychological factors: 
Anxiety can result when a combination of increased internal and external stresses 
overwhelm one’s normal coping abilities or when one’s ability to cope normally is 
lessened for some reason. The psychological factors are summarized below: 
➢ Psychodynamic: When internal competing mental processes, instincts and 
impulses conflict, causing distress.  
➢ Behavioral: Anxiety is a maladaptive learned response to specific past 
experiences and situations that become generalized to future similar situations.  
➢ Spiritual: When people experience a profound, unquenchable emptiness and 
nothingness to their lives, often leading to distress concerning their mortality and 
eventual death (Sarason & Sarason, 2000; Brannon & Feist, 2004).  
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1.4.2.3. Social factors 
Life experiences like death in the family, divorce, job loss, financial loss, 
accident or major illness affect a person’s attitude and response to life situations. 
Long term exposure to abuse, violence, terrorism and poverty may affect an 
individual’s susceptibility to anxiety disorders (Eysenck, 2004). 
1.4.3. Types of Anxiety Disorders:  
 Anxiety disorders can be classified into several categories (ICD-10, 1992; 
Cates et al., 1996; DSM-IV-TR, 2000; Augustin, 2005; Rang et al., 2007). As shown 
in table 2 the different types of anxiety disorders and their clinical symptoms can be 
differentiated. 
Table.1.2. Type of Anxiety Disorders and Their Symptoms 
Anxiety disorder Clinical Symptoms 
Generalized  anxiety 
disorder 
Excessive and unrealistic worry that is difficult to control about 
several life circumstances for 6 months or longer 
Panic  disorder 
(With/without agoraphobia) 
Occurrence of recurrent, unexpected attacks of overwhelming 
fear occurring in association with marked somatic symptoms, 
such as sweating, tachycardia, chest pains, trembling, choking, 
etc. 
Agoraphobia without 
history of panic disorder 
Irrational and often disabling fear of public places or open areas 
Phobic disorders 
Social phobia 
Specific phobias 
Strong fears of specific things or situations, e.g., snake, open 
spaces, flying, social interactions, etc. 
Post-traumatic stress 
disorder 
Anxiety triggered by insistent recall of past stressful/traumatic 
experiences 
Separation anxiety disorder  Difficulty in leaving dear ones 
Obsessive-compulsive 
disorder 
When one is trapped in a pattern of repetitive thoughts and 
behaviors, i.e. recurrent obsessions or compulsions that cause 
marked distress; are time consuming; or interfere significantly 
with normal occupational functioning, social activities, or 
relationships 
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1.4.4. Management of Anxiety 
Anxiety disorders are the most prevalent of psychiatric disorders, yet less 
than 30% of individuals who suffer from anxiety disorders seek treatment (Lepine, 
2002). People with anxiety disorders can benefit from a variety of treatments and 
services. Following an accurate diagnosis, possible treatments include (Barlow, 
2001; NIMH, 2006) psychological treatments and mediation. 
1.4.4.1. Psychological Therapies: 
Psychotherapy is almost always the treatment of choice except in cases 
where anxiety is so severe that immediate relief is necessary to restore functioning 
and to prevent immediate and severe consequences.  This includes the following. 
Behavioral therapy: 
These focus on using techniques such as guided imagery, relaxation training, 
biofeedback (to control stress and muscle tension); progressive desensitization, 
flooding as means to reduce anxiety responses or eliminate specific phobias. The 
person is gradually exposed to the object or situation that is feared. At first, the 
exposure may be only through pictures or audiotapes. Later, if possible, the person 
Acute stress disorder Anxiety reaction which may occur shortly after traumatic 
exposure 
Anxiety disorder due to a 
general medical condition 
Knowledge that one has chronic and perhaps disabling medical 
illness can precipitate anxiety 
Substance induced anxiety 
disorder 
Anxiety related to substance abuse 
Anxiety disorder not 
otherwise specified 
Anxiety reactions which do not fall in any of above categories 
Chapter 1 Introduction 
Dept of Pharmacology 38 JKKMMRF College of Pharmacy 
actually confronts the feared object or situation. Often the therapist will accompany 
him or her to provide support and guidance. 
➢ Cognitive-behavioral therapy (CBT): 
In this therapy, people learn to deal with fears by modifying the ways they 
think and behave. A major aim of CBT and behavioral therapy is to reduce anxiety 
by eliminating beliefs or behaviors that help to maintain the anxiety disorder.  
Research has shown that CBT is effective for several anxiety disorders, particularly 
panic disorder and social phobia (Herbert et al., 2009). It has two components. The 
cognitive component helps people change thinking patterns that keep them from 
overcoming their fears. The behavioral component of CBT seeks to change people's 
reactions to anxiety-provoking situations. A key element of this component is 
exposure, in which people confront the things they fear, i.e., CBT addresses 
underlying “automatic” thoughts and feelings that result from fear, as well as 
specific techniques to reduce or replace maladaptive behavior patterns.  
➢ Psychotherapy: 
Psychotherapy centers on resolution of conflicts and stresses, as well as the 
developmental aspects of anxiety disorders solely through talk therapy. 
Psychotherapy involves talking with a trained mental health professional, such as a 
psychiatrist, psychologist, social worker, or counselor to learn how to deal with 
problems like anxiety disorders (Knekt et al., 2008). 
➢ Psychodynamic therapy:  
This therapy, first suggested by Freud, is based on the premise that primary 
sources of abnormal behavior are unresolved past conflicts and the possibility that 
unacceptable unconscious impulses will enter consciousness.  
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➢ Family therapy and parent training: 
Here the focus is on the family and its dynamics. This is based on the 
assumption that the individuals of a family cannot improve without understanding 
the conflicts that are to be found in the interactions of the family members. Thus, 
each member is expected to contribute to the resolution of the problem being 
addressed (American Psychological Association, 2004; Feldman, 2004).    
Table 1.3 : Major Classes of Medications Used for Various Anxiety Disorders 
Class Generic 
name 
Used 
for 
Mechanism 
of action 
Advantages Limitations 
Anticonvulsants Gabapentin SAD Affect GABA Usually 
effective 
within 2-4 
weeks 
Sedation 
Azaspirones Buspirone GAD Enhances the 
activity of 
serotonin 
Less 
sedating 
than 
benzodiaze-
pines 
Works slowly 
Benzodiazepines Lorazepam    
Clonazepam    
Oxazepam         
Diazepam      
Alprazolam 
GAD,  
SAD,  
Panic 
disorde
r 
Enhance the 
function of 
GABA 
Fast-acting, 
some people 
feel better 
the first day 
Potentially habit-
forming, can 
cause 
drowsiness, can 
produce 
withdrawal 
symptoms, 
discontinuation 
should be done 
slowly 
Beta blockers Propanolol          
Atenolol 
SAD Reduce 
ability to 
produce 
adrenaline 
Fast acting; 
not 
habitforming 
Should not be 
used with pre-
existing medical 
conditions, such 
as asthma, 
congestive heart 
failure, diabetes, 
vascular disease, 
hypothyroidism 
and angina 
pectoris 
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Monoamine 
oxidase 
inhibitors  
(MAOIs) 
Selegilene        
Isocarboxid      
Phenelzine           
Tranylcypromi
ne 
Panic 
disorde
r,  
SAD,  
PTSD 
Block the 
effect of an 
important 
brain enzyme, 
preventing the 
breakdown of 
serotonin and 
noradrenaline 
Effective for 
many 
people, 
especially 
for patients 
not 
responding 
to other 
medications, 
2-6 weeks 
until 
improvemen
t occurs 
Strict dietary 
restrictions and 
potential drug 
interactions, 
changes in blood 
pressure, 
moderate weight 
gain, reduced 
sexual response, 
insomnia 
Selective 
serotonin 
reuptake 
inhibitors 
(SSRIs) 
Citalopram            
Fluvoxamine 
Paroxetine         
Fluoxetine       
Sertraline 
Panic  
disorder
,  
OCD,  
SAD,  
GAD 
Affect the 
concentrati
on of 
serotonin 
Effective, 
with fewer 
side effects 
than other 
medications. 
4-6 weeks 
until 
improvemen
t occurs 
Some people 
experience 
nausea, 
nervousness and 
diminished sex 
drive 
Tricyclic 
antidepressants  
(TCAs) 
Nortriptyline  
Amitriptyline  
Imipramine  
Panic 
disorde
r,  
PTSD,  
OCD  
Regulates 
serotonin 
and/or 
noradrenaline 
in the brain 
Effective for 
many people,  
may take 2-6 
weeks until 
improvement 
occurs. 
Dry mouth, 
constipation, 
blurry vision, 
difficulty 
urinating, 
dizziness, low 
blood pressure, 
moderate weight 
gain, sexual side 
effects 
 
Note. GAD = Generalized anxiety disorder, OCD = Obsessive compulsive disorder, 
PTSD = Post Traumatic stress disorder, SAD=Social anxiety 
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1.4.5. Plants used for management of anxiety 
The World Health Organisation estimates that 80% of the world population 
relies on herbal medicine (Eisenberg et al., 1998). Various plants have been 
investigated for their anxiolytic effects (Carlini, 2003) and many have shown 
marked antianxiety activity. Monoherbal preparations containing Scutellaria 
laterifolia, Centella asiatica, Paullinia cupana, Piper methysticum, Bacopa 
monniera, Cymbopogan citratus, Passiflofa incarnata and Valeriana officinalis were 
subjected to randomised clinical trials to study their effect in alleviation of anxiety 
(Ernst, 2006). According to the reported data, Piper methysticum (Pittler et al., 
2002) and Bacopa monniera, (Stough et al., 2001) are associated with anxiolytic 
activity in humans. In another trial on generalized anxiety disorder (GAD) in 
hospital based clinical set-up, Ocimumn sanctum significantly attenuated generalized 
anxiety disorders and also attenuated its correlated stress and depression 
(Bhattacharyya et al., 2008). 
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CHAPTER 2 
LITRATURE REVIEW 
Literature review is the first and most important step for the proper selection 
of plants and it also forms basis for the planning of any scientific work that has to be 
performed. Due to this reason, the review of literature regarding Syzygium aqueum 
has been done under various divisions like Pharmacognostical, Phytochemical, 
Pharmacological, Ethno medical and also miscellaneous reviews. 
➢ Azza A. A. Galal et al., has reported Neuropharmacological studies on 
Syzygium aromaticum essential oils on International Journal of Pharma science 
ISSN-2320-6810, Vol.5, No.2 (2015); 1013-1018. 
➢ Shabnam Millika et al., has reported Analgesic, Anti-inflammatory and CNS 
activities of Methanolic extract of Syzygium samarangense bark on IOSR 
Journal of pharmacy (e) ISSN:2250-3013, (p) ISSN:2319-4219, 
www.iosrphr.org, vol.3, Dec 2013, pp 12-18. 
➢ Patali Snehalatha. N et al., has reported Antiepileptic activity of Methanolic 
extract of Syzygium cumini seeds in Albino mice on International Journal of 
Pharmacy and Technology, ISSN:0975-766X, vol.5, Issue No.3, Nov 2013, 
5697-5704. 
➢ Shabnam Millika et al., has reported Analgesic, Anti-inflammatory and CNS 
activities of Methanolic extract of Syzygium samarangene leaves on Global 
Journal of Pharmacology 8(1):39-46, 2014, ISSN:1992-0075. 
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➢ Manaharan. T et al., has reported Syzygium aqueum leaf extract and it’s Bio 
active compounds enhance pre-adipocyte differenciation and 2-NBDG 
uptake in 3T3-L1 cells on Research gate, Food chemistry 136 (2013), 354-363. 
➢ Levitah.C et al., has reported Efficacy of Three varieties of Syzygium aqueum 
(Tambis) as Antimicrobial agent and it’s Bio active component on 
International Journal of Science and Clinical laboratory, vol.5,No.1(2014). 
➢ Rabeta et al., has reported Anticancer effect of underutilized fruits (Syzygium 
aqueum, Syzygium malaccense, Syzygium malaccence L.) on International 
Food Research journal20 (2), 2013; 551-556. 
➢ Manaharan.T et al., has reported Flavanoids isolated from Syzygium aquem 
leaf extract as potential Anti-hyperglycaemic agents on Research gate, Food 
chemistry 132(2012), 1802-1807. 
➢ Monemzzaman khandaker. M et al., has reported Bio active costituents, 
Antioxidant and Antimicrobial Activities of Three cultivators of Wax apple 
Fruits on Research Journal of Biotechnology, vol.10, January 2015. 
➢ Nallakurumban. B et al., has reported Phytochemical and Antioxidant 
Properties of Water apple (Syzygium aqueum) and Chapathikalli (Optunica 
ficus indica) on International Journal for Research in Emerging Science and 
Technology,vol.2, Issue 10, Oct 2015, E.ISSN 2349-7610. 
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CHAPTER 3 
AIM AND PLAN OF WORK 
3.1 AIM OF PRESENT STUDY 
In recent year there has been a tremendous increase in demand for herbal 
drugs due to its safety, efficacy and better therapeutic results and also due to its 
economic pricing as compared to synthetic or allopathic drugs, which have several 
therapeutic complications. 
The selection of this plant, Syzygium aqueum was made on the basis of its 
✓ High therapeutic value  
✓ Easy availability 
✓ Degree of research work which is not done  
Very less pharmacological studies have been carried out on the leaves of Syzygium 
aqueum. Hence, I have decided to choose Syzygium aqueum on which detailed studies 
on Preliminary Phytochemical and Pharmacological actions on CNS is done. 
3.2 THE PLAN OF WORK 
The plan of work for the study of Syzygium aqueum was carried out as 
follow. 
Collection and authentication of raw material 
1. Preliminary phytochemical studies 
a. Preparation of extract 
b. Qualitative phytochemical studies 
2. Pharmacological studies 
a. Acute oral Toxicity study 
b. Screening of Anxiolytic activity 
c. Screening of Anticonvulsant activity 
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CHAPTER 4 
PLANT PROFILE 
Plant Classification: 
Kingdom :  Plantae 
Order : Myrtales 
Family : Myrtaceae 
Genus   : Syzygium 
Species               : S.aqueum 
Synonym    : Eugenia aquea 
Local names   : Watery rose apple, Water apple, Bell fruit 
 
Fig. 3.1. Tree of Syzygium aqueum 
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Fig. 3.2. Leaves of Syzygium aqueum 
 
 
Fig. 3.3. Fruits of Syzygium aqueum 
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Plant Description: 
 The Syzygium aqueum (Brum.f) Alston is an evergreen, 3-10 m tall tree, 
ramified until the base, with brown bark, with which the age gets fissured and peels 
off, and thick and irregular foliage. 
 The leaves on short petiole, are opposite, obovate or elliptic-oblong, cordate 
at the base, 5-22 cm long and 3-10 cm broad, of pale green color on the upper page, 
yellowish green below, leathery. 
 The inflorescences are axillar and terminal, on a short peduncle, carrying 3-7 
flowers with 4 spatulate petals, about 0.7 cm long, of pale yellow or pinkish color 
and several stamina, of the same color of petals, up to 2 cm long. 
 The fruits are piriform or bell shaped berries, flattened at the two ends, 1.5-2 
cm long and 2.5-3.5 cm broad, of pink or red color with white or pinkish pulp, 
crunchy or spongy, aqueous, refreshing with a light sweetish taste.  The fruits may 
be seedless or may contain 1-6 seeds, most frequently 1-2 (www.photomazza.com ). 
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CHAPTER 5 
MATERIALS AND METHODS 
5.1 COLLECTION AND IDENTIFICATION 
5.1.1 Collection of specimen: 
The species for the proposed study that is leaves of Syzygium aqueum has 
carefully collected from Angadippuram, Malappuram DT, Kerala. 
5.1.2 Taxonomical identification: 
The plant was positively identified by Dr. Prabhukumar.K.M, Senior 
Scientist and Head, Plant Systematics and Genetic Resourse Divison and CMPR 
Herbaria, Centre for Medicinal Plant Research, Arya Vaidya Sala, Kottakkal.The 
plant was authenticated as Syzygium aqueum (Brum.f.) Alston of Myrtaceae family. 
5.1.3 Shade drying: 
After collection, the leaves of Syzygium aqueum were washed thoroughly 
with water to remove the dirt particles and any other foreign material adheres to 
leaves. Then after, the leaves were wiped off with cotton cloth and transferred to 
newspaper and evenly spreader on to paper. 
The Syzygium aqueum leaves were subjected to shade drying to treat fungus 
until complete dryness of leaves. Then the dried leaves were powdered by mixer 
grinder until to get coarse powder, which was used for further detailed studies, 
extraction with solvent and phytochemical studies. 
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5.2. PRELIMINARY PHYTOCHEMICAL ANALYSIS 
Extraction of Syzygium aqueum leaves: 
Methanol extract: 
 About 250gm of air dried powdered material was taken in 3000ml soxhlet 
apparatus and extracted with petroleum ether until green colour disappear. At the 
end of the day the powder was taken out and dried. After drying it was again packed 
and extracted by using Methanol (S.D. Fine Chemicals Ltd. Mumbai, India) as 
solvent, till colour disappeared. The temperature was maintained at 55ºC-65ºC.  
After that extract was concentrated by distillation and solvent was recovered. The 
final solution was evaporated to dryness. The colour, consistency and yield of 
Methanolic extract were noted. 
Table: 5.1 Nature of extract of Syzygium aqueum 
 
5.3 CHEMICAL TESTS: 
A) Test for carbohydrates: 
1. Molisch’s Test: It consists of treating the compounds of -naphthol and 
concentrated sulphuric acid along the sides of the test tube. 
Purple colour or reddish violet colour was produced at the junction between 
two liquids. (Kokate, C.K et al., 2000) 
S.No. Name of extract Colour Consistency Yield% W/W 
1. Methanolic extract Greenish black Sticky mass 7 
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2. Fehling’s Test: Equal quantity of Fehling’s solution A and B is added. Heat 
gently, brick red precipitate is obtained. 
3. Benedict’s test: To the 5ml of Benedict’s reagent, add 8 drops of solution under 
examination. Mix well, boiling the mixture vigorously for two minutes and then 
cool. Red precipitate is obtained 
B) Test for Alkaloids: 
1. Dragendroff’s Test: To the extract, add 1ml of Dragendroff’s reagent, Orange 
red precipitate is produced. 
2. Wagner’s test: To the extract add Wagner reagent, reddish brown precipitate is 
produced. 
3. Mayer’s Test: To the extract add 1ml or 2ml of Mayer’s reagent, dull white 
precipitate is produced.    
4. Hager’s Test: To the extract add 3ml of Hager’s reagent, yellow Precipitate is 
produced. 
C) Test for Steroids and Sterols: 
1. Liebermann Burchard test: Dissolve the test sample in 2ml of chloroform in a 
dry test tube. Now add 10 drops of acetic anhydride and 2 drops of concentrated 
sulphuric acid. The solution becomes red, then blue and finally bluish green in 
colour. 
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2. Salkowski test: Dissolve the sample of test solution in chloroform and add equal 
volume of conc. sulphuric acid. Bluish red cherry red and purple color is noted 
in chloroform layer, whereas acid assumes marked green fluorescence. 
D) Test for Glycosides: 
1. Legal’s test: Sample is dissolved in pyridine; sodium nitropruside solution is 
added to it and made alkaline. Pink red colour is produced. 
2. Baljet test: To the drug sample, sodium picrate solution is added. Yellow to 
orange colour is produced. 
3. Borntrager test: Add a few ml of dilute sulphuric acid to the test solution. Boil, 
filter and extract the filtrate with ether or chloroform. Then organic layer is 
separated to which ammonia is added, pink, red or violet colour is produced in 
organic layer. 
4.  Killer Killani test: Sample is dissolved in acetic acid containing trace of ferric 
chloride and transferred to the surface of concentrated sulphuric acid. At the junction 
of liquid reddish brown color is produced which gradually becomes blue. 
E) Test for Saponins: 
 Foam test: About 1ml of alcoholic sample is diluted separately with distilled 
water to 20ml, and shaken in graduated cylinder for 15 minutes.1 cm layer of foam 
indicates the presence of saponins. 
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F) Test for Flavonoids: 
Shinoda test: Red colour is produced when the sample, magnesium turnings and 
then concentrated hydrochloric acid is added. 
 Ferric chloride test – Test solution when treated with few drops of Ferric chloride 
solution would result in the formation of blackish red color indicating the presence 
of flavonoids. 
Alkaline reagent Test – Test solution when treated with sodium hydroxide solution, 
shows increase in the intensity of yellow color which would become colorless on 
addition of few drops of dilute Hydrochloric acid, indicates the presence of 
flavonoids. 
Lead acetate solution Test – Test solution when treated with few drops of lead 
acetate (10%) solution would result in the formation of yellow precipitate. 
G) Test for Tri-Terpenoids: 
 In the test tube, 2 or 3 granules of tin was added, and dissolved in a 2ml of 
thionyl chloride solution and test solution is added. Pink colour is produced which 
indicates the presence of triterpenoids. 
H) Tests for Tannins and Phenolic Compounds: 
 The Phenol content in the raw material of caesalpiniasappanextract was 
estimated by spectroscopically method. 
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To 2-3 ml of extract, add few drops of following reagents:  
a)  5% FeCl3 solution: deep blue-black color. 
b)  Lead acetate solution: white precipitate. 
c)  Gelatin solution: white precipitate 
d)  Bromine water:decolouration of bromine water. 
e)  Acetic acid solution: red color solution  
f)  Dilute iodine solution: transient red color. 
g)  Dilute HNO3: reddish to yellow color 
5.4. PHARMACOLOGICAL EVALUATION 
5.4.1. ACUTE ORAL TOXICITY STUDY 
The procedure was followed by using OECD guidelines 423 (Acute toxic 
class method).The acute toxic class method is a step wise procedure with 3 animals 
of single sex per step. Depending on the mortality and / or moribund status of the 
animals, on average 2-4 steps may be necessary to allow judgment on the acute 
toxicity of the test animals while allowing for acceptable data based scientific 
conclusion.  
The method uses defined doses (5, 50, 300, 2000mg/kg body weight) and the 
results allow a substance to be ranked and classified according to the Globally 
Harmonized System (GHS) for the classification of chemical which cause acute 
toxicity. 
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ANIMALS: 
 Female albino mice of 20-30 gm of body weight obtain from Animal House, 
Department of Pharmacology, J.K.K.M.M.R.F. College of pharmacy, Namakkal DT, 
Tamil Nadu.Animals were kept in standard animal house condition. Prior to use, the 
mice were housed in polypropylene cages in group of six animals under natural 
light-dark cycle. They were provided with commercial food pallets and tap water ad 
libitum. Cleaning and sanitation work was done on alternate days. Paddy husk was 
provided as bedding material. All the observations were made at room temperature 
in a noiseless diffusely illuminated room. The cages were maintained clean and all 
experiments were conducted between 8 am to 3 pm. 
PROCEDURE: 
Twelve animals Albino mice, (25-30gm) were selected for studies.  
Most of the crude extracts possess LD50, value more than 2000mg/kg of the 
body weight of the animal used. Dose volume was administered 0.1ml/100gm body 
weight to the animal by oral route. 
After giving the dose toxic signs were observed within 3-4 hours. Body 
weight of the animals before and after administration, onset of toxicity and signs of 
toxicity like changes in the skin and fur, eyes and mucous membrane and also 
respiratory, circulatory, autonomic and central nervous systems activities, motor 
activity and behavior pattern, sign of tremors, convulsion, salivation, diarrhea, 
lethargy and sleep and coma was also to be noted, if any, was observed. The animal 
toxic or death was observed upto 14 days. 
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OBSERVATION 
Acute toxicity studies and evaluation of datas are studied as per the guideline 
of OECD (423). 
No toxicity or death was observed for these given dose levels, in selected and 
treated animals. So the LD50 of the Methanolic extract of leaves of Syzygium 
aqueum was greater than 2000mg/kg (LD50>2000mg/kg). 
 Hence the biological dose was fixed at three levels, 125,250 and 500mg/kg 
body weight for the extract.  
5.4.2. EVALUATION OF ANXIOLYTIC AND ANTICONVULSANT 
ACTIVITY 
Animals: 
Albino mice of either sex 20-30 gm of body weight obtain from Animal 
House, Department of Pharmacology, J.K.K.M.M.R.F. College of Pharmacy, 
(Proposal No. – JKKMMRFCP/IAEC/2017/007) Namakkal DT, Tamil Nadu. 
Animals were kept in standard animal house condition. Prior to use, the mice were 
housed in polypropylene cages in group of six animals under natural light-dark 
cycle. They were provided with commercial food pallets and tap water ad libitum. 
Cleaning and sanitation work was done on alternate days. Paddy husk was provided 
as bedding material. All the observations were made at room temperature in a 
noiseless diffusely illuminated room. The cages were maintained clean and all 
experiments were conducted between 8 am to 3 pm. 
  
Chapter 5 Materials and Methods 
Dept of Pharmacology 56 JKKMMRF College of Pharmacy 
Drugs and Chemicals: 
✓ Diazepam (Calmpose Inj. Ranbaxy, India) 
✓ Pentylenetetrazole (Sigma, USA) 
✓ Methanol extra pure (S.D fine chemicals, Mumbai). 
Experimental Design: 
Animals are divided into 5 groups, each group containing 6 mice. 
➢ Group I: Normal control mice fed with vehicle only. 
➢ Group II: Mice treated with Diazepam 5mg/kg 
➢ Group III: Mice treated with 125 mg/kg Methanolic extract of Syzygium aqueum 
➢ Group IV: Mice treated with 250 mg/kg Methanolic extract of Syzygium aquem 
➢ Group V: Mice treated with 500 mg/kg Methanolic extract of Syzygium aqueum 
5.4.2.1. EVALUATION OF ANXIOLYTIC ACTIVITY 
5.4.2.1.1. Elevated Plus Maze (EPM) Test. 
The EPM test is the most frequently employed model for the assessment of 
the anxiolytic activity of novel substances (R.G.Liser 1987). The elevated plus maze 
apparatus consisted of two perpendicular open arms (50 X 10 cm) and two 
perpendicular enclosed arms (50 X 10 X 40 cm). The entire maze was constructed of 
wood and elevated 50 cm above floor. The maze was placed inside a light (25 lx) 
and sound attenuated room. 
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The animals were divided into five groups, each group comprised six mice. 
Different groups were treated with distilled water (10 mL/kg), diazepam (5 mg/kg), 
and Methanolic Extract of Syzygium aqueum at doses of 125, 250, and 500 mg/kg, 
BW. Thirty minutes later, the rat was placed in the center platform of the maze 
facing the enclosed arm and was observed for 10 min. The parameters assessed 
were the time spent in open and enclosed arms and numbers of open and enclosed 
arms entries. All tests were taped by using a video camera and every precaution was 
taken to ensure that no external stimuli could evoke anxiety in the mice. After each 
test, the maze was carefully cleaned up with a wet tissue paper (70% ethanol 
solution) to eliminate the interference of the olfactory cues on the next rat 
(Peng.W.H et al.,2000). 
5.4.2.1.2. Open Field Test.  
The study was conducted according to method previously described by 
Brown et al with some modifications. The apparatus was made up of plywood 
measuring 72 cm X 72 cm X 36 cm. One of the walls was made of transparent 
Perspex glass to ensure that the mouse under investigation is visible to the observer. 
The floor, made of cardboard, was divided into 16 equal squares (18 cm X 18 cm) 
with blue marker and a central square drawn with black marker. The cardboard was 
covered with a transparent Plexiglas. The animals were divided into five groups; 
each group comprised six rats. Different groups were treated with distilled water 
(10 mL/kg), diazepam (5 mg/kg), and Methanolic extract of Syzygium aqueum at 
doses of 125, 250, and 500 mg/kg, BW. Thirty minutes later, each mouse was 
placed individually at the corner of the arena and its behavior monitored for 5 min. 
The number of rearings and number of square crossed by each mouse was recorded. 
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The apparatus was wiped between observations with 70% ethyl alcohol and allowed 
to dry to remove any olfactory cue. 
5.4.2.1.3. Rota rod: 
The equipment of Rotarod was used to evaluate motor coordination produced 
by drugs in animals. The mice were trained before the experiment to acquire the 
capacity to remain for 300 s on a diameter rod, rotating at 20 rpm. Two or three 
trials were sufficient for the animals to learn this task. Thirty mice were divided into 
five groups; each group comprised six rats. Different groups were treated with 
distilled water (10 mL/kg), diazepam (5 mg/kg), and Methanolic extract of leaves of 
Syzygium aqueum at doses of 125, 250, and 500 mg/kg, BW. Then, the animals 
were placed in the four paws on the rotating bar, which is 2.5 cm in diameter and 25 
cm high from the floor. The animals were observed for a period of five minutes. 
The difference between the fall-off time of the mice before and after treatment was 
considered as an index of muscle relaxation (Farkas.S et al., 2005). 
5.4.2. EVALUATION OF ANTICONVULSANT ACTIVITY 
5.4.2.1. Pentylenetetrazole Induced Convulsions: 
Pentylenetetrazole (PTZ) induced convulsions test was performed to evaluate 
anticonvulsant property of drugs (Ahmadiani.A et al.,).Thirty male mice were 
divided into five groups, each group comprised six mice. Different groups were 
treated with distilled water (10 mL/kg), diazepam (5 mg/kg), and Methanolic 
extract of Syzygium aqueum at doses of 125, 250, and 500 mg/kg, BW. Thirty 
minutes later, convulsions were induced by the intraperitoneal administration of 60 
mg/kg BW of PTZ. Following the administration of PTZ, mice were placed in 
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separate transparent plexiglass cages (25 × 15 × 10 cm) and were observed for the 
occurrence of seizures over a 30 min time period. Latency of convulsions (the time 
prior to the onset of tonic convulsions), duration of tonic convulsions, and mortality 
protection (percentage of deaths in 24 h) were recorded (R.S. Fischer, 1989). 
5.4.2.2. Maximal Electro Shock (MES) Induced Convulsions: 
 The animals were divided into five groups, each group comprised six mice. 
Different groups were treated with distilled water (10 mL/kg), diazepam (5 mg/kg), 
and Methanolic extract of Syzygium aqueum at doses of 125, 250, and 500 mg/kg, 
BW. Thirty minutes later, convulsions were induced in all the groups of animals 
using electro convulsiometer. A 60 Hz alternating current of 150 mA for 2 s was 
delivered through the ear electrodes (Balamurukan.G.et al.,). The animal was 
observed for the occurrence of tonic hind limb extension. 
5.5. Data analysis 
Results of the experiments and observations were expressed as mean ± 
standard deviation (SD). The significance of differences between groups was 
determined using one-way analysis of variance (ANOVA) followed by at least one 
of the following post hoc tests: Dunnett’s multiple comparison tests 𝑃< 0.05 where 
level of significance was considered for each test. The data is presented as mean ± 
S.D. 
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CHAPTER 6 
RESULTS AND DISCUSSION 
Based on literature review, the leaves of Syzygium aqueum of family 
Myrtaceae was collected, authenticated and the project was carried out. The result of 
the present study show that the Methanol extract of Syzygium aqueum leaves shows 
significant anticonvulsant and anxiolytic activities. 
6.2 PRILIMINARY PHYTOCHEMICAL STUDIES 
Table No. 6.1. Percentage Yield of Syzygium aqueum 
Name of extract Yield(%w/w) 
Methanol 7 
 
The extract obtained were subjected to qualitative Phytochemical test to find 
out the active constituents. 
Table No.6.2: Qualitative Phytochemical analysis of the extract 
TEST FOR PHYTOCONSTITUENTS RESULT 
Saponins _ 
Alkaloids + 
Glycosides + 
Tannins and phenolic compounds + 
Carbohydrate + 
Terpenoids + 
Flavonoids + 
Steroids + 
 
    (+) - Present (-) - Absent 
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DISCUSSION: 
The preliminary Phytochemical studies were done in the Methanolic extract 
of Syzygium aqueum leaves, the result suggest that presence of Alkaloids, 
Carbohydrate, Terpenoids, flavonoids, Steroids, phenolic compounds and 
tannins. 
6.3 PHARMACOLOGICAL STUDIES  
6.3.1 ACUTE ORAL TOXICITY STUDIES 
The acute oral toxicity of the Methanolic extract of Syzygium aqueum was 
carried out as per OECD 423-guidelines (Acute toxic class method). Acute toxicity 
studies revealed that LD50>2000mg/kg for the extract. Hence, the biological dose 
was fixed at 125, 250mg and 500mg/kg body weight.  
6.3.2. EVALUATION OF ANXIOLYTIC ACTIVITY 
Elevated plus maze: 
Administration of diazepam (5mg/kg) significantly increases number of 
open arm entries, time spent in open arms and the number of rearings in open arm. 
They showed a reduction in the time spent in closed arm. Plant extracts treated mice 
exhibited significant increase in the number of open arm entries. The number of arm 
entries, but decreases in time spent in closed arm as shown in the table 6.3.   
Open field test: 
There was significant anxiolytic activity observed with diazepam, plant 
extracts when compared to control. In the open field test, plant extract showed 
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significant increase in number of rearings, number of squares crossed and number of 
assisted rearings during 5 min intervals of test as compared with control as show in 
table 6.4.  
Rota rod: 
Table 6.5.shows the effects of Methanolic extract of leaves of Syzygium 
aqueumin the Rotarod test, a method used for evaluating motor coordination and 
presence of any muscle griping effect. It revealed that there was significantly 
increased grip force and fall time after administration of Methanolic extract of 
Syzygium aquem (125, 250, and 500 mg/kg) when compared to control. All the 
plant extract treated animals retained on the rotating rod for more than 276.35 ± 
7.58 s at 500 mg/kg as shown in Table 6.5 indicate the Methanolic extract of 
Syzygium aqueum to be devoid of neurotoxicity. 
Table. 6.3. Effect of Methanolic extract of Syzygium aqueum on Elevated plus 
maze in mice 
Group Treatment Dose 
Time spent in 
open arm (s) 
Entries in open 
arm 
I Saline 10ml/Kg 40.25±4.41 3.98±0.52 
II Diazepam 5mg/kg 239.59±3.52** 12.64±0.47** 
III Plant extract 125mg/kg 100.83±3.97 6.48±0.39 
IV Plant extract 250mg/kg 173.81±4.32* 6.53±0.42* 
V Plant extract 500mg/kg 213.92±4.80** 10.32±0.21** 
 
The data represent the mean ±S.D (n=6) *p<0.01, **p<0.001significantly different 
compared to normal control and diazepam 
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Table 6.4. Effect of Methanolic extract of Syzygium aqueum on Open field test 
in mice 
Group Treatment Dose 
Number of 
square crossed 
Number of 
rearing 
I Saline 10ml/kg 40.3±2.1 10.1±1.4 
II Diazepam 5mg/kg 29.5±3.6** 8.2±1.8** 
III Plant extract 125mg/kg 22.9±2.4 5.4±2.3 
IV Plant extract 250mg/kg 24.7±3.2* 7.3±3.5* 
V Plant extract 500mg/kg 26.4±2.8** 9.3±1.2** 
 
 The data represent the mean ±S.D (n=6) *p<0.01, **p<0.001 significantly 
different compared to normal control and diazepam. 
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Table.6.5. Effect of Methanolic extract of Syzygium aqueum leaves on Rota rod 
performance 
Group Treatment Dose 
Experimental mean 
time(10min) (s) 
Before After 60 min 
I Control 10ml/kg 180.21±9.1 128.10±7.6 
II Diazepam 5mg/kg 157.61±6.9** 112.90±6.3 
III Plant extract 125mg/kg 140.82±5.7 100.39±7.2 
IV Plant extract 250mg/kg 145.41±3.6* 97.46±5.9 
V Plant extract 500mg/kg 152.13±5.8** 94.53±6.5 
 
The data represent the mean ±S.D (n=6) *p<0.01, **P<0.001 significantly different 
compared to normal control and diazepam. 
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6.3.3. EVALUATION OF ANTICONVULSANT ACTIVITY 
6.3.1. PTZ Induced Convulsion: 
Pentylenetetrazole produced tonic seizures in the entire animals used. A dose 
of 125 mg/kg of Methanolic extract of leaves of Syzygium aqueum protected 
33.33% of the animals against seizures and did not affect the onset (latency) of 
seizures to any significant extent. Methanolic extract of leaves of Syzygium aqueum 
at the dose of 250 and 500 mg/kg protected 50.0% and 100% of the mice against 
seizures and increased the latency of the seizures (Table 6.6). 
6.3.2. Maximal Electro Shock Model: 
Maximal electroshock produced hind limb tonic extension (HLTE) in all the 
animals. The vehicle treated mice showed tonic hind limb extension for duration 
of12.88 ± 0.35 s. Administration of Methanolic extraction of leaves of Syzygium 
aqueum (125–500 mg/kg) showed a dose dependent increase in the delay of the 
onset time of seizures induced by maximal electroshock induced convulsion and 
also decreased duration of tonic hind limb extension (Table 6.7). 
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Table.6.6. Effect of Methanolic extract of leaves of Syzygium aqueum on PTZ 
induzed convulsions in mice 
 
The data represents the mean S.D ± (n=6) *p<0.1, **p<0.001significantly different 
compared to normal control and diazepam. 
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Group Treatment 
Latency of 
Tonic 
convulsion (s) 
Duration of 
Tonic 
convulsions (s) 
Mortality 
(% death) 
% 
Protection 
I Control 100.20±3.34 446.10±5.19 6/6(100) 0.0 
II Diazepam (5mg/kg) 478.34±6.07** 126.69±1.93** 0/6(0.0) 100 
III Plant extract (125mg/kg) 141.43±1.98 216.29±1.23 4/6(66.66) 33.33 
IV Plant extract (250mg/kg) 298.16±4.45* 189.19±1.72* 3/6(50.00) 50.0 
V Plant extract (500mg/kg) 416.42±6.14** 137.11±2.61** 0/6(0.0) 100 
Chapter 6 Results and Discussion 
Dept of Pharmacology 68 JKKMMRF College of Pharmacy 
Table.6.7. Effect of Methanolic extract of Syzygium aqueum on Tonic seizures 
induced by MES method in mice 
Group Treatment 
Seizure onset time 
(s) 
Duration of Tonic 
Hind Limb 
Extension (Sec.) 
I Control 8.38±1.88 12.88±0.35 
II Diazepam(5mg/kg) 59.88±1.35** 2.63±1.72** 
III Plant extract(125mg/kg) 28.81±1.10 8.28±1.19 
IV Plant extract(250 mg/kg) 32.43±1.44* 7.44±1.01* 
V Plant extract(500mg/kg) 48.84±1.25** 3.21±1.25** 
 
The data represent the mean ±S.D (n=6) *p<0.05, **p<0.001 significantly different 
compared to normal control and diazepam.     
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CHAPTER 7 
SUMMARY AND CONCLUSION 
 The leaves of Syzygium aqueum belonging to family Myrtaceae has been 
examined to gain an insight of its Phytochemical and pharmacological behaviors. 
 The preliminary phytochemical investigation of Methanolic extract of leaves 
of Syzygium aquem  showed the presence of Carbohydrate, Alkaloids, 
Phytosteroids, Flavonoids, Phenolic compounds and Tannins. 
 The pharmacological and acute toxicity studies of Methanolic extract was 
performed by following, OECD-423 guidelines (Acute toxic class method). No 
mortality or acute toxicity was observed upto 2000mg/kg of body weight. 
 Medicinal plants have served as sources of readily accessible, inexpensive, 
and effective medication since the earliest times known to man. Several 
ethnomedicinal plants have been found to possess neurobehavioral profile and serve 
as alternative to modern medicine. Biological evaluation and scientific validation of 
the ethnomedicinal plants are the need of the hour. The present study was proposed 
to assess anxiolytic, and anticonvulsant effects of methanolic extract of leaves of an 
ethnomedicinal plant, Syzygium aqueum. 
Anxiety disorders are due to involvement of GABAergic, serotonergic, 
involvement. The adrenergic and dopamanergic system have also been shown to 
play a role in anxiety. BZA have been extensively, used for the last 40 years to treat 
several forms of anxiety, but due to their unwanted side effects, alternative treatment 
strategies with favorable side effect profiles. Medicinal plants are a good source to 
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find new remedies for these disorders. Despite the wide spread traditional use of 
Syzygium aqueum for treating various disorders there are no reports of scientific 
evaluation of its anxiolytic and anticonvulsant activity. The present work 
demonstrates that the Syzygium aqueum leaf extract had anxiolytic activity in mice 
by Elevated Plus Maze, Rotarod and Open field models. 
Elevated Plus Maze is used to evaluate psychomotor performance and 
emotional aspects of rodents. Results showed that plant extracts treated mice 
exhibited significant increase in the number of open arm entries but decreases in 
time spent in closed arm, which reflects plants anxiolytic property.  
The open field test is used to evaluate the animal emotional state. The open 
field model examines anxiety related behavior characterized by the normal aversion 
of the animal to an open area. Thus, animals removed from their acclimatized cage 
and placed in environment express anxiety and fear, by showing alteration in all or 
some parameters. Mice treated with extract showed increase in number of rearings 
and time spent in the center.  
Rota rod test, the difference in the fall of time from the rotating rod between 
the vehicle and extract treated groups were taken as an index of muscle relaxation. 
Plant extract showed significant decrease in the locomotory score and fall of time of 
the mice from the rotating rod.  
The results of the present laboratory animal study indicate that Methanolic 
extract of Syzygium aqueum leaf extract possesses anticonvulsant activity. The 
present study demonstrated the anticonvulsant effects of the methanolic extract of 
Syzygium aqueum in both chemically and electrically induced seizures in mice. The 
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extract exhibited dose dependent protection in the MES and PTZ induced 
convulsions. Nevertheless, in unprotected animals, the extract significantly increased 
seizure latency and reduced seizure duration compared with the control group in all 
two models at all tested doses. The effect of most of antiepileptic agents is to 
enhance the response to GABA by facilitating the opening of GABA-activated 
chloride channels. GABA receptors were involved in epilepsy and their direct 
activation would have an antiepileptic effect. 
The anticonvulsant, anxiolytic, and sedative effects of benzodiazepines like 
diazepam are mostly attributed to enhance the action of gamma-aminobutyric acid 
(GABAA) (Yemitan O.K. etal.,2005). Actually, benzodiazepines bind to the gamma 
subunit of the GABAA receptor, due to which a structural modification of the 
receptor results in an increase in GABAA receptor activity. Benzodiazepines do not 
substitute for GABA, which bind at the alpha subunit, but increase the frequency of 
channel opening events, which leads to an increase in chloride ion conductance and 
inhibition of the action potential (Muhammed.N et al.,and Garcia 2006). According 
to some researchers, the anxiolytic action of benzodiazepines may be due to the 
direct activation of glycine synapses in the brain (Muhammed.N et al., and 
P.Brambilla, 2013). This may explain the mechanism of action of the tested extract 
as well, because it is clear from the results that the effect of the extract was similar 
to diazepam. 
Previous phytochemicals reported in the literature, various Flavonoids, 
glycosides, Alkaloids and triterpenoids, isolated from Syzygium aquem would be the 
effective constituents for their anxiolytic and anticonvulsant effect. 
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In conclusion, Methanolic extract of Syzygium aqueum possesses anxiolytic 
and anticonvulsant effects and these findings collaborate with the ethnomedicinal 
uses of this plant. The isolation of active chemicals from this plant might serve as 
lead compounds for the synthesis of drugs which could be used in the management 
of these nervous disorders. 
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